Background Potential benefits of rapamycin or rapalogs for treating people with tuberous
sclerosis complex (TSC) have been shown. Currently everolimus (a rapalog) is only …

Background Systemic mammalian target of rapamycin (mTOR) inhibitors are currently used
in many dermatologic indications. Their topical use is recent and poorly codified. Objective …

Abstract Background and Objectives Facial angiofibromas are disfiguring facial lesions,
present in up to 80% of patients with tuberous sclerosis complex. Recent elucidation of the …

Importance Inhibitors of mammalian target of rapamycin complex 1, such as sirolimus,
effectively target skin lesions in tuberous sclerosis complex (TSC). However, systemic …

Abstract Background Facial angiofibromas (FAs) are a major feature of tuberous sclerosis
complex (TSC). Topical rapamycin can successfully treat FAs. A new stabilized cream …

Importance Most patients with tuberous sclerosis complex (TSC), an autosomal-dominant
disorder that is caused by the constitutive activation of mammalian target of rapamycin …

Background Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous
syndrome causing hamartomatous growths in multiple organs. Facial angiofibromas occur in …

Background Tuberous sclerosis complex (TSC) is an autosomal dominant disorder causing
multiple hamartomas. Treatment of TSC lesions with mammalian target of rapamycin …

Background Data on long-term topical sirolimus treatment of the cutaneous manifestations of
tuberous sclerosis complex are rare. Objective To evaluate the long-term benefit and …

Tuberous sclerosis complex is an autosomal dominant disorder that often manifests early in
life with cutaneous features, and it is important that dermatologists who care for children …